|Articles|June 11, 2014

Europe Sees Pressure to Reduce Environmental Impact of Pharmaceuticals

Author(s)editortest

Pressure is mounting on European legislators to introduce tighter regulations at both the European Union (EU) and national levels on the potentially harmful impact of pharmaceuticals on the environment.

Pressure is mounting on European legislators to introduce tighter regulations at both the European Union (EU) and national levels on the potentially harmful impact of pharmaceuticals on the environment.

Politicians, environmentalists and even medicines regulators are calling for action in the face of increasing evidence that pharmaceutical chemicals used through the whole lifecycle of medicines from production through to disposal are posing a bigger than previously anticipated threat to the environment.

There are, however, divided opinions on what needs to be done. Sean Milmo outlines how the different stakeholders want to tackle the issue in this Pharmaceutical Technology article.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.